Barbara dives deeper into rural hospital closures and the growing rural health care crisis. She discusses new payer policy approaches as well as efforts in the virtual care and digital tool space. She concludes her article with insightful suggestions for pharmaceutical companies to partner with payers in addressing this growing health care gap.
Gene therapies bring the prospect of cures once unimaginable. The potential is exciting, but we cannot assume today's healthcare system can accommodate the financial burden expected from the gene therapy pipeline. Innovative therapies come with high manufacturing and delivery costs and target low patient numbers leading to million-dollar price points.
DUMs are an important cost savings tool, but the administrative burden can be high. What are some strategies that can be employed to mitigate that burden?
Dig into the developing role of alternative drug makers and their impact on the drug pricing landscape with Barbara Henry.
